# Evaluation of Primex's PGX Assay to Assess the Clinical Utility of Pharmacogenomics

> **NCT02336269** · — · UNKNOWN · sponsor: **Primex Clinical Laboratories, Inc.** · enrollment: 100000 (estimated)

## Conditions studied

- Patients on Medications Metabolized Via CYP450

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02336269
- **Lead sponsor:** Primex Clinical Laboratories, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-10
- **Primary completion:** 2017-10
- **Final completion:** 2019-10
- **Target enrollment:** 100000 (ESTIMATED)
- **Last updated:** 2015-01-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02336269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02336269, "Evaluation of Primex's PGX Assay to Assess the Clinical Utility of Pharmacogenomics". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT02336269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*